News | June 03, 2022
Evonik to build new lipid production facility for mRNA-based therapies in U.S.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Both companies have been selected for stand-by production by German government
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
The transaction is expected to close in the first quarter of 2022
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Subscribe To Our Newsletter & Stay Updated
